Biochemical and clinical benefits of unilateral adrenalectomy in patients with subclinical hypercortisolism and bilateral adrenal incidentalomas

Eur J Endocrinol. 2015 Dec;173(6):719-25. doi: 10.1530/EJE-15-0566. Epub 2015 Sep 1.

Abstract

Objective: The treatment of subclinical hypercortisolism in patients with bilateral adrenal incidentalomas (AI) is debatable. We aimed to compare the biochemical and clinical outcome of unilateral adrenalectomy vs a conservative approach in these patients.

Design: Retrospective study.

Methods: The study included 33 patients with bilateral AI; 14 patients underwent unilateral adrenalectomy of the largest lesion (surgical group), whereas 19 patients were followed up (follow-up group). At baseline and at each follow-up visit, we measured 0800 h plasma ACTH, midnight serum cortisol (MSF), 24-h urinary-free cortisol (UFC) and serum cortisol following a standard 2-day low-dose-dexamethasone-suppression test (LDDST). We evaluated the following comorbidities: arterial hypertension, impaired glucose tolerance or diabetes mellitus, dyslipidemia and osteoporosis.

Results: Baseline demographic, clinical characteristics and the duration of follow-up (53.9±21.3 vs 51.8±20.1 months, for the surgical vs the follow-up group) were similar between groups. At the last follow-up visit the surgical group had a significant reduction in post-LDDST cortisol (2.4±1.6 vs 6.7±3.9 μg/dl, P=0.002), MSF (4.3±2 vs 8.8±4.6 μg/dl, P=0.006) and 24-h UFC (50.1±21.1 vs 117.9±42.4 μg/24 h, P=0.0007) and a significant rise in mean±s.d. morning plasma ACTH levels (22.2±9.6 vs 6.9±4.8 pg/ml, P=0.002). Improvement in co-morbidities was seen only in the surgical group, whereas no changes were noted in the follow-up group.

Conclusions: Our early results show that removal of the largest lesion offers significant improvement both to cortisol excess and its metabolic consequences, without the debilitating effects of bilateral adrenalectomy. A larger number of patients, as well as a longer follow-up, are required before drawing solid conclusions.

Publication types

  • Clinical Study

MeSH terms

  • Adrenal Cortex Neoplasms / metabolism
  • Adrenal Cortex Neoplasms / surgery*
  • Adrenal Gland Neoplasms / epidemiology
  • Adrenal Gland Neoplasms / metabolism
  • Adrenal Gland Neoplasms / surgery*
  • Adrenalectomy / methods*
  • Adrenocortical Adenoma / epidemiology
  • Adrenocortical Adenoma / metabolism
  • Adrenocortical Adenoma / surgery*
  • Aged
  • Asymptomatic Diseases*
  • Case-Control Studies
  • Cohort Studies
  • Comorbidity
  • Cushing Syndrome / epidemiology
  • Cushing Syndrome / metabolism
  • Cushing Syndrome / surgery*
  • Diabetes Mellitus / epidemiology
  • Dyslipidemias / epidemiology
  • Female
  • Glucose Intolerance / epidemiology
  • Humans
  • Hydrocortisone / blood
  • Hydrocortisone / urine
  • Hypertension / epidemiology
  • Male
  • Middle Aged
  • Osteoporosis / epidemiology
  • Retrospective Studies
  • Treatment Outcome

Substances

  • Hydrocortisone

Supplementary concepts

  • Adrenal incidentaloma